PROFILE OF DANNEX AYRTON STARWIN PLC

Three local giants in the pharmaceutical manufacturing business, Dannex Limited, which was established in 1964, Ayrton Drug Manufacturing Limited, which was incorporated in 1965 and Starwin Products Limited, which was formed in 1960, successfully merged their operations to form Dannex Ayrton Starwin PLC. The company was incorporated on December19, 2019 and subsequently listed on the Ghana Stock Exchange on January 15, 2020 under the trade name DASPHARMA.

Through the consolidation of the manufacturing of assets, human capital, distribution and sales channels, as well as financial capabilities, the creation of Dannex Ayrton Starwin Plc, offers a more efficient and profitable pharmaceutical company. The company is poised to become the largest pharmaceutical manufacturing company in Ghana with staff strength of over 600.

It has the largest distribution network in the industry, cutting across the whole country with over 2,000 active wholesale and retail customers in the network,with a range of 80 plus products, all manufactured here in Ghana. The range of products are categorized under the following: Analgesics, Hematinics, anti-tussives, dermatological products, anti-convulsing and anti-asthmatics.

Some of the company’s key products include Durol, Virol, Samalin, Teeder, Koffex, ORS, Rapinol, Asmadrin and Milk of Magnesia. Most of these are market leaders in their field and are wildly patronized in the country.

The company has a strong Research and Development team which continues to develop cutting edge products for the nation’s health needs. The Team continually scan the globe for international partnerships for technology transfer.

Dannex Ayrton Starwin Plc’s combined market capitalization would be enough to attract potential investors to help boost the growth agenda, liquidity and dividend yield to enhance its shareholder value.